Symmetrical Dimethylarginine Predicts Mortality in the General Population | Zendy

M. Odette Gore | Zendy; Nicole Lüneburg | Zendy; Edzard Schwedhelm | Zendy; Colby Ayers | Zendy; Maike Anderssohn | Zendy; Amit Khera | Zendy; Dorothee Atzler | Zendy; James A. de Lemos | Zendy; Peter J. Grant | Zendy; Darren K. McGuire | Zendy; Rainer H. Böger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Symmetrical Dimethylarginine Predicts Mortality in the General Population

Author(s) -

M. Odette Gore,

Nicole Lüneburg,

Edzard Schwedhelm,

Colby Ayers,

Maike Anderssohn,

Amit Khera,

Dorothee Atzler,

James A. de Lemos,

Peter J. Grant,

Darren K. McGuire,

Rainer H. Böger

Publication year - 2013

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.113.301219

Subject(s) - medicine , hazard ratio , cardiology , confidence interval , population , asymmetric dimethylarginine , arginine , biology , biochemistry , environmental health , amino acid

Increased asymmetrical dimethylarginine (ADMA), a NO synthase inhibitor, and its congener symmetrical dimethylarginine (SDMA), predict cardiovascular and all-cause mortality in at-risk populations. Their prognostic value in the general population remains uncertain. We investigated the correlations of SDMA and ADMA with atherosclerosis and cardiovascular/all-cause mortality in the Dallas Heart Study, a multiethnic probability-based cohort aged 30 to 65 years.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research